ArriVent BioPharma (AVBP) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ArriVent BioPharma (AVBP) has outperformed Sana Biotechnology (SANA) over the past year, losing 19.7% versus a loss of 37.3%. Sana Biotechnology is the larger company by market cap ($835.2 million vs $824.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | SANA |
|---|---|---|
| Share price | $16.73 | $2.79 |
| Market cap | $824.92M | $835.22M |
| 1-day change | +0.12% | 0.00% |
| YTD return | -16.95% | -31.45% |
| 1-year return | -19.74% | -37.30% |
| 5-year return | — | -86.58% |
| EPS (TTM) | $-3.62 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $6.55 |
| 52-week low | $11.36 | $2.61 |
| Distance from 52-week high | -53.31% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +82.31% | +202.15% |
| Average volume | 916.04K | 3.14M |
| Shares outstanding | 49.31M | 299.36M |
| Employees | 77 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVBP has outperformed SANA by 17.6 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
AVBP vs SANA FAQ
Which is bigger, ArriVent BioPharma or Sana Biotechnology?
Sana Biotechnology (SANA) is larger, with a market capitalization of $835.22M compared with $824.92M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, AVBP or SANA?
AVBP returned -19.74% over the past 12 months, compared with -37.30% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Sana Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ArriVent BioPharma and Biotechnology: Biological Products (No Diagnostic Substances) for Sana Biotechnology.